Recombinant Mouse PCSK9 Protein (Met1-Gln694), MlgG1 Fc-tagged
|Product Overview :
|Recombinant Mouse PCSK9 Protein (NP_705793.1) (Met1-Gln694) was produced by HEK293 Cells expression system. This protein was expressed with the Fc region of mouse IgG1 at the C-terminus.
- Gene Information
- Related Products
|Proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as NARC1 (neural apoptosis regulated convertase), which is a newly identified human secretory subtilase belonging to the proteinase K subfamily of the secretory subtilase family. PCSK9 protein is an enzyme which in humans is encoded by the PCSK9 gene with orthologs found across many species. It is expressed in neuroepithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells. PCSK9 protein is highly expressed in the liver and regulates low density lipoprotein receptor (LDLR) protein levels. Inhibition of PCSK9 protein function is currently being explored as a means of lowering cholesterol levels. Thereby, PCSK9 protein is regarded as a new strategy to treat hypercholesterolemia. PCSK9 protein contributes to cholesterol homeostasis and may have a role in the differentiation of cortical neurons.
|Predicted N Terminal :
|Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
|Molecular Mass :
|The recombinant mouse PCSK9 consists of 894 amino acids and predicts a molecular mass of 97.6 kDa.
|Protein length :
|< 1.0 EU per μg protein as determined by the LAL method.
|> 95 % as determined by SDS-PAGE.
|Samples are stable for up to twelve months from date of receipt at -70 centigrade.
|Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4ºC before opening to recover the entire contents.
|In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
|Gene Name :
|Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Mus musculus ]
|Official Symbol :
|PCSK9; NARC-1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409;
|Gene ID :
|mRNA Refseq :
|Protein Refseq :
|UniProt ID :
|◆ Recombinant Protein
|Recombinant Rhesus Macaque PCSK9 Protein, His (Fc)-Avi-tagged
|Recombinant Human PCSK9 Protein, Strep-tagged
|Active Recombinant Human PCSK9 Protein, His-tagged
|Recombinant Human PCSK9 Protein, His-tagged
|Recombinant Mouse Pcsk9 Protein, His-tagged
|Recombinant Mouse PCSK9 cell lysate
|Recombinant Rhesus PCSK9 cell lysate
|Recombinant Rat PCSK9 cell lysate
|◆ Assay kits
|PCSK9-LDLR TR-FRET Assay Kit
|PCSK9(D374T)-LDLR TR-FRET Assay Kit
|PCSK9[Biotinylated]-LDLR Binding Assay Kit
|PCSK9-BIRC2 in vitro Binding Assay Kit
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Customer Reviews (3)Write a review
In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.
It promoted cell growth and proliferation.
High catalytic efficiency.
Ask a Question for All PCSK9 Products
Required fields are marked with *
My Review for All PCSK9 Products
Required fields are marked with *